Premium Company Profile United Therapeutics

United Therapeutics was originally created as a biotechnology company focused on the development and commercialization of products for patients with chronic and life threatening cardiovascular, cancer and infectious diseases. In 2000, the company entered the telemedicine products and services market through a series of acquisitions which included Cooke Pharma, Medicomp and Telemedical Procedures.

Report Highlights
United Therapeutics' research and development efforts are focused primarily on Identification and development of Prostacyclin Analogs, Glycobiology Antiviral Agents and Immunotherapeutic Monoclonal Antibodies The company's total revenues increased at a CAGR of 52% during 2002-2006, from $30 million to $160 million. This represents an absolute total growth of +$130 million for total revenues. The company's biggest contributor to revenue growth during 2002-2006 was product sales Remodulin The company's biggest contributor to sales growth out to 2010 will be product sales of Inhaled Remodulin. Revenues from Inhaled Remodulin are expected to reach $146 million in 2010. This represents an absolute growth of +$146 million, which is 39% of United Therapeutics' total forecast growth
[Studien Infos ausblenden]

Overview 1
Catalyst 1
Summary 1
Company Structure 6
Company Overview and Key Facts 6
Business Description 7
History 8
Locations and Subsidiaries 11
Company Financials 13
Stock Market Performance 13
P&L 15
Balance Sheet 17
Cash Flow 17
Business Segment Performance 18
Products & Services 19
Marketed Products 19
Pipeline Products 20
Historical Product Sales 24
AC Forecast Product Sales 26
Competitors and Strategic Business Relationships 28
Key Competitors 28
Key Suppliers 28
Key Clients 29
Shareholding Structure 30
Strategy 31
Company View 31
Corporate Strategy 32
SWOT Analysis 34
Overview 34
Strengths 35
Weaknesses 37
Opportunities 38
Threats 39
Value Chain Analysis 41
Overview 41
Discovery and Product Development 41
Manufacturing 42
Sales 42
Scorecard 44
Overview 44
Scorecard Analysis 45
Key Employees 46
List of Key Employees 46
Key Employee Biographies 47
Financial and Operational Overview 48
Financial and Operational Overview 48
APPENDIX 50
Ask the analyst 50
Datamonitor consulting 50
Disclaimer 50
[Inhaltsverzeichnis ausblenden]

Table 1: United Therapeutics - Key Facts 6
Table 2: United Therapeutics – Locations and Subsidiaries 11
Table 3: United Therapeutics - Year-End Share Price and Market Capitalization, 2002-2006 ($) 13
Table 4: United Therapeutics - Key Events Impacting Share Price Performance 14
Table 5: United Therapeutics - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 15
Table 6: United Therapeutics - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 17
Table 7: United Therapeutics - Balance Sheet, 2002-2006 ($ Mn) 17
Table 8: United Therapeutics – Cash Flow, 2002-2006 ($ Mn) 17
Table 9: United Therapeutics - Revenue Breakdown by Division, 2002-2006 ($ Mn) 18
Table 10: United Therapeutics - Marketed Products 19
Table 11: United Therapeutics - In-house Pipeline Products 20
Table 12: United Therapeutics - Collaboration Products 23
Table 13: United Therapeutics - Historical Product Sales, 2002-2006 ($ Mn) 24
Table 14: United Therapeutics - Forecast Sales, 2006-2010 ($ Mn) 26
Table 15: United Therapeutics – Key Competitors 28
Table 16: United Therapeutics – Key Suppliers 29
Table 17: United Therapeutics – Key Clients 29
Table 18: United Therapeutics - Key Shareholders 30
Table 19: United Therapeutics - SWOT Analysis Summary 34
Table 20: United Therapeutics – Value Chain Analysis 41
Table 21: United Therapeutics - Scorecard 44
Table 22: United Therapeutics - Key Employees 46
Table 23: United Therapeutics – Financial and Operational Overview 48

[Tabellenverzeichnis ausblenden]